Arcutis Biotherapeutics Inc (OQ:ARQT)

Sector:  Healthcare Industry:  Biotechnology & Medical Research
See Regulatory Filings on SEC
Company Contact
Address: 3027 Townsgate Road, Suite 300
Tel: 1-805-4185006
IR: See website
Key People
Patrick J. Heron
Independent Chairman of the Board
Kimberly Lathroum
Vice President of Marketing
Todd Franklin Watanabe
President, Chief Executive Officer, Director
David W. Osborne
Co-Founder, Chief Technical Officer
Scott L. Burrows
Chief Financial Officer, Principal Accounting Officer
Matthew R. Moore
Senior Vice President, Chief Business Officer
Patricia A. Turney
Senior Vice President - Operations
Rajvir Madan
Chief Digital and Information Officer
Courtney Barton
Chief Compliance Officer, Vice President, Chief of Staff
Jay Ramsinghani
Vice President of Commercial Strategy and Operations
Business Overview
Arcutis Biotherapeutics Inc is a United States-based biopharmaceutical company. The Company focuses on developing treatments for unmet needs in immune-mediated dermatological diseases or immune-dermatology. Its strategy is to identify and develop treatments against validated biological targets in dermatology that deliver a differentiated clinical profile that addresses shortcomings of existing therapies in targeted indications.
Financial Overview
For the three months ended 31 March 2021, ArcutisBiotherapeutics Inc revenues was not reported. Net lossincreased 29% to $36M. Higher net loss reflects Stock-basedCompensation in SGA increase from $574K to $7M (expense),General and administrative - Balancing increase from $2.9Mto $7.5M (expense), Stock-based Compensation in R&Dincrease from $416K to $1.5M (expense).
Employees: 54 as of Dec 31, 2020
Reporting Currency: U.S. Dollars
Enterprise value: $807.69M as of Mar 31, 2021
Annual revenue (TTM): $0.00M as of Mar 31, 2021
EBITDA (TTM): -$143.89M as of Mar 31, 2021
Net annual income (TTM): -$143.71M as of Mar 31, 2021
Free cash flow (TTM): -$139.06M as of Mar 31, 2021
Net Debt Last Fiscal Year: N/A
Shares outstanding: 50,205,046 as of Apr 30, 2021
TTM: Trailing Twelve Months
EBITDA: Earnings Before Interest, Taxes, Depreciation, & Amortization

Thank you for visiting We have detected you cannot see ads being served on our site due to blocking. Unfortunately, due to the high cost of data, we cannot serve the requested page without the accompanied ads.

If you wish to consider using a browser that blocks ads, please subscribe. Our packages start at $1.00 plus tax for the first month.

Alternatively, if you have installed ad-blocking software, please disable it (sometimes a complete uninstall is necessary). If you are in private browsing mode and do not want to subscribe, please disable tracking protection while visiting our website.

Thank you for using Insider Tracking.